News
RBC Capital’s Brian Abrahams just told Vertex shareholders to hold their horses—literally. Despite Vertex stock closing at ...
RBC Capital slightly trimmed Vertex Pharmaceuticals’ price target from $423 to $420, but the firm’s rating stayed the course.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback